FPWR and PWSA|USA Request Regulatory Flexibility & Review of NDA for Intranasal Carbetocin
We request the flexibility afforded to other orphan indications when considering whether applications for treatments for PWS should be accepted for review. In a continuation of our joint advocacy efforts supporting the full review of potential drugs for PWS, FPWR and PWSA | USA have submitted a petition letter to the FDA requesting that they...
Harmony Biosciences is seeking people with PWS between the ages of 6 – 65 to enroll in Clinical Trial
Click Here to View and Download Harmony Biosciences’ PWS Trial Infographic
Prader-Willi Syndrome Association Announces First Virtual Convention
FOR IMMEDIATE RELEASE: January 14, 2021 Sarasota, Florida: Prader-Willi Syndrome Association | USA (PWSA | USA) is pleased to announce its upcoming 36th National Convention is moving to an all-new virtual format. Due to the ongoing health concerns brought forth by the COVID-19 pandemic, the organization will provide members of the Prader-Willi syndrome community with a variety...
News Release: Rhythm Wins FDA Approval for Obesity Drug Imcivree
Rhythm Pharmaceuticals Inc., a company developing medicines for rare genetic disorders of obesity, has won FDA approval for its first product, Imcivree (setmelanotide), following a priority review. The drug is designed to restore a biological pathway that, when disrupted, can lead to constant hunger. The approval covers the treatment of three types of ultrarare early...